amantadine has been researched along with Chorea in 21 studies
amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source
Chorea: Involuntary, forcible, rapid, jerky movements that may be subtle or become confluent, markedly altering normal patterns of movement. Hypotonia and pendular reflexes are often associated. Conditions which feature recurrent or persistent episodes of chorea as a primary manifestation of disease are referred to as CHOREATIC DISORDERS. Chorea is also a frequent manifestation of BASAL GANGLIA DISEASES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Huntington chorea, like levodopa-induced dyskinesias, may be responsive to amantadine hydrochloride treatment." | 9.10 | A randomized trial of amantadine in Huntington disease. ( Dewey, RB; O'Suilleabhain, P, 2003) |
| "We report an 80-year-old woman with hemichorea probably due to amantadine hydrochloride." | 7.69 | [A case of multiple cerebral infarctions associated with hemichorea induced by amantadine hydrochloride]. ( Morimatsu, M; Negoro, K; Tsuda, N, 1994) |
| "Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder." | 5.51 | Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine. ( Ahn, JH; Cho, JW; Ha, J; Kim, JS; Kim, JW; Kim, M; Lee, JH; Na, BS; Youn, J, 2019) |
| "Chorea scores were lower with amantadine (usually 400 mg/d) than placebo, with a median reduction in extremity chorea at rest of 36% (p = 0." | 5.10 | Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. ( Chase, TN; Farmer, C; Gillespie, M; Morris, MJ; Mosby, K; Verhagen Metman, L; Wuu, J, 2002) |
| "Huntington chorea, like levodopa-induced dyskinesias, may be responsive to amantadine hydrochloride treatment." | 5.10 | A randomized trial of amantadine in Huntington disease. ( Dewey, RB; O'Suilleabhain, P, 2003) |
| "If HD chorea requires treatment, clinicians should prescribe tetrabenazine (up to 100 mg/day), amantadine (300-400 mg/day), or riluzole (200 mg/day) (Level B) for varying degrees of expected benefit." | 3.78 | Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. ( Armstrong, MJ; Miyasaki, JM, 2012) |
| "We report an 80-year-old woman with hemichorea probably due to amantadine hydrochloride." | 3.69 | [A case of multiple cerebral infarctions associated with hemichorea induced by amantadine hydrochloride]. ( Morimatsu, M; Negoro, K; Tsuda, N, 1994) |
| "We have studied the urinary excretion of 1,4-methylhistamine (1,4-MeHm), 5-hydroxyindole-3-acetic acid (5-HIAA) and homovanillic acid (HVA) in patients with Parkinson's disease, choreiform movements and essential tremor." | 3.65 | Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa. ( Fleming, AM; Lenman, JA; Reid, A; Turnbull, MJ, 1977) |
| "Cranial CT revealed a chronic subdural hematoma (CSDH) that covered the left parietal lobe." | 2.58 | [Chorea due to chronic subdural hematoma]. ( Kanemaru, K; Murayama, S; Sengoku, R; Shibukawa, M; Shiraishi, T; Takanashi, S, 2018) |
| "Paraneoplastic chorea is typically a subacute progressive hyperkinetic movement disorder." | 1.51 | Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine. ( Ahn, JH; Cho, JW; Ha, J; Kim, JS; Kim, JW; Kim, M; Lee, JH; Na, BS; Youn, J, 2019) |
| "Treatment included induction of coma while a native immune response matured; rabies vaccine was not administered." | 1.33 | Survival after treatment of rabies with induction of coma. ( Amlie-Lefond, CM; Chusid, MJ; Ghanayem, NS; Hoffman, GM; Rupprecht, CE; Schwabe, MJ; Tieves, KS; Willoughby, RE, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 9 (42.86) | 18.7374 |
| 1990's | 1 (4.76) | 18.2507 |
| 2000's | 5 (23.81) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ha, J | 2 |
| Na, BS | 2 |
| Ahn, JH | 2 |
| Kim, M | 2 |
| Kim, JW | 2 |
| Lee, JH | 2 |
| Cho, JW | 2 |
| Kim, JS | 2 |
| Youn, J | 2 |
| Doher, N | 1 |
| Gupta, HV | 1 |
| Shiraishi, T | 1 |
| Sengoku, R | 1 |
| Takanashi, S | 1 |
| Shibukawa, M | 1 |
| Kanemaru, K | 1 |
| Murayama, S | 1 |
| Park, H | 1 |
| Jeon, BS | 1 |
| Shin, JH | 1 |
| Park, SH | 1 |
| Armstrong, MJ | 1 |
| Miyasaki, JM | 1 |
| Verhagen Metman, L | 1 |
| Morris, MJ | 1 |
| Farmer, C | 1 |
| Gillespie, M | 1 |
| Mosby, K | 1 |
| Wuu, J | 1 |
| Chase, TN | 1 |
| O'Suilleabhain, P | 1 |
| Dewey, RB | 1 |
| Furukawa, Y | 1 |
| Filiano, JJ | 1 |
| Kish, SJ | 1 |
| Willoughby, RE | 1 |
| Tieves, KS | 1 |
| Hoffman, GM | 1 |
| Ghanayem, NS | 1 |
| Amlie-Lefond, CM | 1 |
| Schwabe, MJ | 1 |
| Chusid, MJ | 1 |
| Rupprecht, CE | 1 |
| Bonelli, RM | 1 |
| Hofmann, P | 1 |
| Tsuda, N | 1 |
| Negoro, K | 1 |
| Morimatsu, M | 1 |
| Gray, MW | 1 |
| Herzberg, L | 1 |
| Lerman, JA | 1 |
| Turnbull, MJ | 2 |
| Victoratos, G | 1 |
| Agnoli, A | 1 |
| Ruggieri, S | 1 |
| Casacchia, M | 1 |
| Lenman, JA | 1 |
| Reid, A | 1 |
| Fleming, AM | 1 |
| Mundinger, F | 1 |
| Milios, E | 1 |
| Godwin-Austen, RB | 1 |
| Frears, CC | 1 |
| Bergmann, S | 1 |
| Parkes, JD | 1 |
| Knill-Jones, RP | 1 |
| Schergna, E | 1 |
| Ferro-Milone, F | 1 |
| Parisen-Toldin, P | 1 |
| Borromei, A | 1 |
| Lorizio, A | 1 |
| Ecari, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Amantadine for the Treatment of Behavioral Disturbance in Frontotemporal Dementia (FTD)[NCT00127114] | Phase 4 | 0 participants (Actual) | Interventional | 2005-09-30 | Withdrawn (stopped due to No funding and exclusion criteria were to stringent.) | ||
| Combining a Dopamine Agonist and Selective Serotonin Reuptake Inhibitor for Treatment of Depression: A Double-Blind, Randomized Study[NCT00086307] | Phase 2 | 39 participants (Actual) | Interventional | 2004-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Montgomery Asberg Depression Rating Scale (MADRS) is a 10 item scale for assessing the severity of depression. Items are rated on a scale of 0 to 6, so the maximum score is 60 and the minimum is 0, where 60 is the most severe depression. Scores of 18 or greater are generally considered to indicate a moderate level of depression. (NCT00086307)
Timeframe: Weekly
| Intervention | Score on a scale (Least Squares Mean) |
|---|---|
| Pramipexole | 22.629 |
| Escitalopram | 26.102 |
| Escitalopram and Pramipexole | 29.455 |
2 reviews available for amantadine and Chorea
| Article | Year |
|---|---|
[Chorea due to chronic subdural hematoma].
Topics: Aged, 80 and over; Amantadine; Chorea; Female; Hematoma, Subdural, Chronic; Humans; Magnetic Resonan | 2018 |
A systematic review of the treatment studies in Huntington's disease since 1990.
Topics: Amantadine; Antipsychotic Agents; Chorea; Depression; Humans; Huntington Disease; Neuroprotective Ag | 2007 |
4 trials available for amantadine and Chorea
| Article | Year |
|---|---|
Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine.
Topics: Adult; Aged; Amantadine; Chorea; Cognition; Cross-Over Studies; Dopamine Agents; Double-Blind Method | 2002 |
A randomized trial of amantadine in Huntington disease.
Topics: Amantadine; Chorea; Cross-Over Studies; Elbow; Female; Humans; Huntington Disease; Male; Mental Proc | 2003 |
Restatement and prospectives of ergot alkaloids in clinical neurology and psychiatry.
Topics: Aged; Amantadine; Basal Ganglia Diseases; Bromocriptine; Chorea; Clinical Trials as Topic; Depressio | 1978 |
Combined treatment of parkinsonism with L-dopa and amantadine.
Topics: Aged; Amantadine; Chorea; Clinical Trials as Topic; Dihydroxyphenylalanine; Female; Humans; Hypotens | 1970 |
15 other studies available for amantadine and Chorea
| Article | Year |
|---|---|
Anti-CV2/CRMP5 Paraneoplastic Chorea Effectively Managed with Intravenous Amantadine.
Topics: Administration, Intravenous; Amantadine; Autoantibodies; Carrier Proteins; Chorea; Dopamine Agents; | 2019 |
Paraneoplastic Chorea Managed with Intravenous Amantadine.
Topics: Amantadine; Chorea; Humans; Huntington Disease | 2019 |
Author Response to Letter to the Editor.
Topics: Amantadine; Chorea; Humans | 2019 |
A patient with 41 CAG repeats in SCA17 presenting with parkinsonism and chorea.
Topics: Amantadine; Antiparkinson Agents; Benzothiazoles; Brain; Chorea; Humans; Levodopa; Male; Middle Aged | 2016 |
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology.
Topics: Adult; Amantadine; Anticonvulsants; Chorea; Evidence-Based Medicine; Humans; Huntington Disease; Ril | 2012 |
Amantadine for levodopa-induced choreic dyskinesia in compound heterozygotes for GCH1 mutations.
Topics: Amantadine; Antiparkinson Agents; Child; Chorea; Dopamine Agents; Dyskinesia, Drug-Induced; GTP Cycl | 2004 |
Survival after treatment of rabies with induction of coma.
Topics: Adolescent; Amantadine; Anesthetics; Animals; Antiviral Agents; Athetosis; Benzodiazepines; Bites an | 2005 |
[A case of multiple cerebral infarctions associated with hemichorea induced by amantadine hydrochloride].
Topics: Aged; Aged, 80 and over; Amantadine; Cerebral Infarction; Chorea; Female; Humans; Tomography, Emissi | 1994 |
Letter: Amantadine in chorea.
Topics: Aged; Amantadine; Chorea; Drug Evaluation; Homovanillic Acid; Humans; Huntington Disease; Hydroxyind | 1975 |
Urinary monoamine metabolite excretion in disorders of movement. Effects of amantadine and levodopa.
Topics: Amantadine; Chorea; Homovanillic Acid; Humans; Hydroxyindoleacetic Acid; Levodopa; Methylhistamines; | 1977 |
[Experiences with memantine in the treatment of severe spastic and extrapyramidal movement disorders in combination with stereotaxic surgery].
Topics: Adolescent; Adult; Aged; Amantadine; Athetosis; Basal Ganglia Diseases; Cerebral Palsy; Child; Chore | 1985 |
[Recent therapeutic conquests in extrapyramidal syndromes].
Topics: Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Amantadine; Athetosis; Brain Diseases; Central | 1970 |
[Changes in the electroencephalogram during treatment with amantadine].
Topics: Amantadine; Brain; Chorea; Electroencephalography; Extrapyramidal Tracts; Humans; Movement Disorders | 1971 |
[On the therapeutic use of amantadine hydrochloride in non-parkinsonian hyperkinetic syndromes].
Topics: Adult; Amantadine; Athetosis; Brain Diseases; Brain Injuries; Cerebrovascular Disorders; Child; Chor | 1971 |
[Clinical and electroencephalographic observations on the action of amantadine in the dystonic-athetosic disorders of infentile cerebral paralysis].
Topics: Adolescent; Amantadine; Athetosis; Brain; Cerebral Palsy; Child; Child, Preschool; Chorea; Electroen | 1971 |